**Author details**

Qigui Li\* and Brandon Pybus Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA

\*Address all correspondence to: qigui.li.civ@mail.mil

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**85**

*Pharmacokinetic and Pharmacodynamic Profiles of Rapid- and Slow-Acting Antimalarial Drugs*

chemotherapy. Parasitologia. 1999;**41**:301-308. PMID: 10697872

actatropica.2005.06.009

cid/ciy213

bmj.330.7487.317

[8] Mutabingwa TK. Artemisininbased combination therapies (ACTs): Best hope for malaria treatment but inaccessible to the needy! Acta Tropica. 2005;**95**:305-315. DOI: 10.1016/j.

[9] Plewes K, Kingston HWF, Ghose A, Wattanakul T, Hassan MMU, Haider MS, et al. Acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe *falciparum* malaria: A randomized, controlled, open-label trial. Clinical Infectious Diseases. 2018;**67**:991-999. DOI: 10.1093/

[10] Fanello C, Onyamboko M, Lee SJ, Woodrow C, Setaphan S, Chotivanich K, et al. Post-treatment haemolysis in African children with hyperparasitaemic *falciparum* malaria; a randomized comparison of artesunate and quinine. BMC Infectious Diseases. 2017;**17**:575. DOI: 10.1186/s12879-017-2678-0

[11] Whitty CJ, Ansah E, Reyburn H. Treating severe malaria. BMJ. 2005;**330**:317-318. DOI: 10.1136/

[12] Davis TM, Phuong HL, Ilett KF, Hung NC, Batty KT, Phuong VD, et al. Pharmacokinetics and

pharmacodynamics of intravenousartesunate in severe *falciparum* malaria. Antimicrobial Agents and Chemotherapy. 2001;**45**:181-186. DOI:

[13] Dondorp A, Nosten F, Stepniewska K, Day N, White N. South East Asian quinine artesunate malaria trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe *falciparum* malaria: A randomised trial. Lancet. 2005;**366**:717-725. DOI: 10.1016/

10.1128/AAC.45.1.181-186.2001

S0140-6736(05)67176-0

*DOI: http://dx.doi.org/10.5772/intechopen.83505*

[1] Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in *Plasmodium falciparum* malaria. The New England Journal of Medicine. 2009;**361**:455-467. DOI:

10.1056/NEJMoa0808859

**References**

f1000research.14874.1

AAC.00835-15

s12916-018-1156-x

10.1056/NEJMp1108322

DOI: 10.1155/2018/7465254

[7] White NJ. Delaying antimalarial drug resistance with combination

[2] Mathews ES, Odom John AR. Tackling resistance: Emerging

antimalarials and new parasite targets in the era of elimination. F1000Research. 2018;**7**:pii: F1000. DOI: 10.12688/

[3] Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of *Plasmodium falciparum* malaria multidrug resistance to

artemisinin and piperaquine in Western

Cambodia: Dihydroartemisininpiperaquine open-label multicenter clinical assessment. Antimicrobial Agents and Chemotherapy. 2015;**59**:4719-4726. DOI: 10.1128/

[4] Tyagi RK, Gleeson PJ, Arnold L, Tahar R, Prieur E, Decosterd L, et al. High-level artemisinin-resistance with quinine co-resistance emerges in *P. falciparum* malaria under in vivo artesunate pressure. BMC Medicine. 2018;**16**:181. DOI: 10.1186/

[5] Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, et al. The threat of artemisinin-resistant malaria. The New England Journal of Medicine. 2011;**365**:1073-1075. DOI:

[6] Afaya A, Salia SM, Adatara P, Afaya RA, Suglo S, Japiong M. Patients' knowledge of artemisinin-based combination therapy treatment and its impact on patient adherence. Journal of Tropical Medicine. 2018;**2018**:7465254.

*Pharmacokinetic and Pharmacodynamic Profiles of Rapid- and Slow-Acting Antimalarial Drugs DOI: http://dx.doi.org/10.5772/intechopen.83505*
